Laurion Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Laurion Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,293,686	Closed	-$823K	–	421
2025 Q1	$823K	Buy	1,293,686 +45,322	+4%	+$35.1K	0.02%	182
2024 Q4	$1.29M	Hold	1,248,364	–	–	0.02%	201
2024 Q3	$1.47M	Sell	1,248,364 -278,023	-18%	-$353K	0.02%	171
2024 Q2	$1.86M	Buy	1,526,387 +762,200	+100%	+$1.52M	0.02%	232
2024 Q1	$1.67M	Sell	764,187 -329,734	-30%	-$609K	0.01%	345
2023 Q4	$1.7M	Sell	1,093,921 -94,304	-8%	-$124K	0.01%	311
2023 Q3	$1.53M	Hold	1,188,225	–	–	0.01%	351
2023 Q2	$2.04M	Hold	1,188,225	–	–	0.01%	315
2023 Q1	$1.79M	Sell	1,188,225 -82,675	-7%	-$187K	0.01%	279
2022 Q4	$2.03M	Hold	1,270,900	–	–	0.01%	307
2022 Q3	$1.84M	Hold	1,270,900	–	–	0.01%	334
2022 Q2	$2.33M	Buy	+1,270,900	New	+$2.43M	0.04%	221

Other funds holding CTMX

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Laurion Capital Management's CTMX Position: Q2 2025 in Review

Laurion Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2025, closing a stake of 1,293,686 shares — an estimated $823K sold.

Laurion Capital Management first reported a position in CTMX in Q2 2022 and held it in 12 quarters. The position peaked at $2.33M in Q2 2022. 83 funds tracked by Wall St. Rank hold CTMX as of Q2 2025.

Laurion Capital Management reported no remaining CytomX Therapeutics position as of Q2 2025 after selling out during the quarter.
Laurion Capital Management sold 1,293,686 CytomX Therapeutics shares in Q2 2025, an estimated $823K.
Laurion Capital Management first reported a position in CytomX Therapeutics in Q2 2022 and held it in 12 quarters.
Laurion Capital Management's CytomX Therapeutics position peaked at $2.33M in Q2 2022.
83 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2025.

Based on Laurion Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.